Revisiting IPOs for Potential Investment
For those looking to make calculated, long-term investments, the start of a new year often brings fresh opportunities in the initial public offering (IPO) landscape. While many companies are entering the market, a select few offer considerable potential for both growth and stability.
Even for conservative investors, it’s essential to consider recent IPOs that may fit within a long-term strategy—these stocks could become valuable additions to a buy-and-hold portfolio.
One company making waves in the healthcare sector is particularly intriguing for those interested in biotechnology.
Highlighting Recent IPO Achievements
The past year has shown investors why they shouldn't overlook recent IPOs, even if they typically exhibit higher risk characteristics.
For example, AI cloud computing firm CoreWeave debuted in March 2025 and has since achieved remarkable growth, boasting a nearly 123% increase. Short-term traders saw even higher gains in the early days, but long-term holders continue to benefit.
Medline has also demonstrated that IPOs aren't exclusively risky startups. Established long before going public in December 2025, it now commands a market cap exceeding $55 billion, shattering the myth that only new companies can successfully launch through an IPO.
Smithfield Foods, known for its beloved bacon products, made its long-awaited public offering in January 2025, enjoying modest stock growth alongside a welcoming dividend yield of 4.44%, which is appealing to income-focused investors.
With its IPO on January 9, Aktis Oncology, specializing in radiopharmaceuticals, is poised to join this list of success stories in the years ahead.
The Significance of Radiopharmaceuticals
Aktis Oncology is at the forefront of developing radiopharmaceuticals, an innovative area within nuclear medicine that utilizes radioactive drugs for diagnostic and therapeutic purposes in conditions like cancer and heart disease.
This field of medicine combines radioactive isotopes with specific targeting modules, enabling precise delivery of radiation to damaged cells while protecting healthy tissue—a crucial advancement over traditional radiology methods.
Industry forecasts suggest a bright future for this sector, with the value of the global nuclear medicine market projected to soar from nearly $18 billion to around $35 billion by 2030. This equates to a robust compound annual growth rate of approximately 10.16%, positioning it as a lucrative area of healthcare investment.
Aktis Oncology specifically benefits from its strategic location in North America, which represents a significant portion of this market, with the U.S. taking the lead.
Aktis Oncology: A Rising Biotech Star
Recent developments indicate a resurgence of biotech IPOs as the market stabilizes after experiencing funding interruptions in prior years.
Aktis Oncology made headlines as the first biotech IPO of 2026, securing a notable $318 million in funding, resulting in a strong market cap of $3.34 billion.
Led by a team of experts proficient in drug development and regulatory processes, Aktis is well-positioned to navigate the complexities of bringing its innovative products to market.
Focusing on targeted alpha radiopharmaceuticals, the company taps into unique technology that promises to revolutionize cancer treatment by selectively attacking solid tumors while minimizing collateral damage to surrounding healthy cells.
Strategic Partnerships and Future Prospects
Aktis Oncology is a young but ambitious firm, currently in clinical stages of development. Its IPO caught the attention of industry giant Eli Lilly, reflecting the potential they see in this partnership.
Eli Lilly's investment of $100 million in AKTS shares solidifies a continuing collaboration initiated in 2024 aimed at advancing tumor-targeting treatments. Additionally, Lilly previously committed $60 million in cash, enhancing their stake in Aktis and signaling confidence in the company's future success.
This backing is particularly significant given Eli Lilly's impressive market position as a leading pharmaceutical entity, following a remarkable growth trajectory that saw its profits surge nearly 109% from the previous year. As Eli Lilly prepares to release its upcoming financial results, further positive developments may bolster Aktis's market presence.
All in all, this robust support from Eli Lilly positions Aktis Oncology favorably as they aim for milestones in treatment discoveries, ushering in an exciting set of opportunities in the biotechnology landscape.
Frequently Asked Questions
What is Aktis Oncology, and what do they specialize in?
Aktis Oncology is a biotechnology company focused on developing radiopharmaceuticals for cancer treatment and diagnostics, utilizing innovative techniques to improve patient outcomes.
Why are IPOs considered risky investments?
IPOs are often viewed as risky due to the volatility of newly listed stocks and the uncertainty surrounding a company's market performance post-launch.
What has been Eli Lilly's involvement with Aktis Oncology?
Eli Lilly has invested significantly in Aktis Oncology, supporting its development of tumor-targeting radiopharmaceuticals and strengthening their collaborative efforts.
How large is the global nuclear medicine market?
The global nuclear medicine market is forecasted to grow from approximately $18 billion to nearly $35 billion by 2030, indicating substantial growth potential.
What are target alpha radiopharmaceuticals?
Targeted alpha radiopharmaceuticals are specialized cancer treatments that administer localized radiation to tumors, sparing healthy tissues, aimed at enhancing treatment efficacy.
